KATHLEEN HEMSCHOOT: Open Payments
NPI 1891132684 · ATLANTIC HIGHLANDS, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,551 in 83 payments from 13 companies in 2025. Trend: 2023 $1,740 · 2024 $1,772 · 2025 $1,551
Food & beverage: $1,551
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 26 | $522 |
| AstraZeneca Pharmaceuticals LP | 10 | $278 |
| ABBVIE INC. | 17 | $271 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 10 | $151 |
| GlaxoSmithKline, LLC. | 6 | $100 |
| Amgen Inc. | 5 | $83 |
| Lilly USA, LLC | 3 | $46 |
| Cumberland Pharmaceuticals, Inc. | 1 | $21 |
| Seqirus USA Inc | 1 | $19 |
| Exact Sciences Corporation | 1 | $17 |
Products named: Ozempic, XIFAXAN, FARXIGA, VRAYLAR, QULIPTA, BREZTRI, Wegovy, TRELEGY ELLIPTA.
Industry payments across NJ — which companies pay providers there.
